NanoSomix Inc.
http://www.nanosomix.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From NanoSomix Inc.
Alzheimer’s Disease: Moving Toward The Era Of Diagnostic Certainty
With more than 13 million people in the US expected to have Alzheimer’s disease (AD) by 2050, an increasing number of companies are focused on developing reliable AD diagnostics designed to facilitate early detection and treatment. Although the field remains in its relative infancy, researchers are gaining greater diagnostic certainty through a combination of diagnostic approaches, and over the next decade, the AD diagnostics market is projected to reach a US market value of at least $1 billion to $3 billion per year.
NanoSomiX: Blood Test For Early Alzheimer’s Detection
Envision a simple blood test that can detect the presence of Alzheimer’s disease up to 10 years in advance of a standard clinical diagnosis. NanoSomiX Inc. is developing technology that evaluates brain-derived exosomes and reveals biological changes that are implicated in the pathogenesis of AD.
Start-Up Previews, November 2014
The emerging life sciences companies profiled in the November issue of Start-Up: ImmuneXcite, Inivata, Lumoptik, NanoSomiX, and Scholar Rock.
NanoSomiX Inc.
Envision a simple blood test that can detect the presence of Alzheimer’s disease up to 10 years in advance of a standard clinical diagnosis. NanoSomiX Inc. is developing technology that evaluates brain-derived exosomes and reveals biological changes that are implicated in the pathogenesis of AD.
Company Information
- Industry
-
Laboratory Testing Services
- Anatomical Pathology
-
In Vitro Diagnostics
- Biosensors
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice